J&J-Pharmacyclics drug shows potential in high-risk leukemia patients

February 17, 2015 3:29 PM

10 0

(Reuters) - Pharmacyclics Inc said its cancer drug developed with a Johnson & Johnson unit improved overall response rate in high-risk leukemia patients.

Those administered with Imbruvica showed an overall response rate of 88 percent, while 76.6 percent survived without the disease getting worse at 24 months.

Also read: Trump and Pence hit new lows in Fox poll

Read more

To category page